Payment overview · 2025
General Payments
$174.91
9 reported records · 6 companies
Healthcare provider profile · identity verified
Kristopher J Kaufmann, DO
Allopathic & Osteopathic Physicians|Family Medicine · BOLIVAR, MO · NPI 1023029998
Verified facts
What the public records show
CMS Open Payments records show Kristopher J Kaufmann, DO received $174.91 in general payments during 2025 across 9 reported records.
Abbott Laboratories accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.69 | 54.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.60 | 10.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.42 | 9.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.11 | 9.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.61 | 8.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.48 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.91 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $94.69 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 507 | 119 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 388 | 72 |
| Lisinopril | Lisinopril | 367 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 67 |
| Gabapentin | Gabapentin | 283 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 264 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 53 |
| Omeprazole | Omeprazole | 231 | 61 |
| Losartan Potassium | Losartan Potassium | 212 | 55 |
| Potassium Chloride | Potassium Chloride | 200 | 47 |
| Furosemide | Furosemide | 189 | 47 |
| Metformin Hcl | Metformin Hcl | 185 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 41 |
| Alprazolam | Alprazolam | 175 | 31 |
| Prednisone | Prednisone | 160 | 86 |
| Sertraline Hcl | Sertraline Hcl | 156 | 39 |
| Montelukast Sodium | Montelukast Sodium | 153 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 33 |
| Trazodone Hcl | Trazodone Hcl | 142 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 25 |
| Valsartan | Valsartan | 129 | 31 |
| Tramadol Hcl | Tramadol Hcl | 128 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 123 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 117 | 17 |
| Buspirone Hcl | Buspirone Hcl | 113 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 36 |
| Metformin Hcl Er | Metformin Hcl | 110 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 24 |
| Meloxicam | Meloxicam | 103 | 36 |
| Carvedilol | Carvedilol | 102 | 21 |
| Famotidine | Famotidine | 99 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 18 |
| Ozempic | Semaglutide | 94 | 19 |
| Lovastatin | Lovastatin | 93 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 31 |
| Nifedipine Er | Nifedipine | 87 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 17 |
| Simvastatin | Simvastatin | 75 | 24 |
| Eliquis | Apixaban | 74 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 51 |
| Spironolactone | Spironolactone | 72 | 18 |
| Clonazepam | Clonazepam | 69 | 16 |
| Celecoxib | Celecoxib | 67 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 18 |
| Xarelto | Rivaroxaban | 67 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Baclofen | Baclofen | 59 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 14 |
| Warfarin Sodium | Warfarin Sodium | 57 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | suppressed |
| Pregabalin | Pregabalin | 56 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | 17 |
| Ezetimibe | Ezetimibe | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 14 |
| Finasteride | Finasteride | 48 | 15 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Irbesartan | Irbesartan | 44 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 11 |
| Nystatin | Nystatin | 42 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 11 |
| Atenolol | Atenolol | 38 | 12 |
| Linzess | Linaclotide | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 23 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 12 |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 14 |
| Fluconazole | Fluconazole | 20 | 12 |
| Glipizide | Glipizide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Nystop | Nystatin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.91 · 9 records | Abbott Laboratories | Cologuard Collection Kit, FREESTYLE LIBRE, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error